보고서 요약(국문)

시장 개요
전 세계 파브리병 치료 시장 규모는 2022년 18억 7,670만 달러에 달했으며, 2030년까지 32억 8,720만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 전 세계 파브리병 치료 시장은 예측 기간(2023~2030년) 동안 연평균 7.4%의 성장률을 기록할 것으로 전망됩니다. 주요 시장 트렌드는 정밀 의학과 맞춤형 치료에 대한 관심 증가입니다.
예를 들어, 환자의 유전적 및 분자적 특성에 맞춘 맞춤형 치료는 치료 결과를 개선하고 환자에게 효과가 없는 치료법을 피하도록 도울 것으로 기대됩니다. 이는 환자 경험 개선, 인구 건강 증진, 비용 절감이라는 세 가지 목표(Triple Aim)와도 부합합니다.
파브리병은 알파-갈락토시다제 A(AGA)라는 효소의 결핍 또는 기능 장애를 특징으로 하는 희귀 유전 질환입니다. 이 효소는 글로보트리아실세라마이드(GL-3) 또는 글로보트리아실스핑고신(Lyso-GL-3)이라는 지방 물질을 분해하는 역할을 합니다. 다양한 조직과 장기에 GL-3 또는 Lyso-GL-3가 축적되면 심각한 증상과 합병증을 유발할 수 있습니다.
파브리병 치료 시장은 질병에 대한 인식 및 진단 증가, 샤페론 요법 및 효소 대체 요법과 같은 새로운 치료법에 대한 수요 증가, 치료 옵션의 발전, 연구 개발 활동 증가, 기술 발전 등의 요인에 의해 성장하고 있습니다.
예를 들어, 2023년 3월, 키에시 그룹의 계열사인 키에시 글로벌 레어 디지즈와 바이오제약 회사인 프로탈릭스 바이오테라퓨틱스는 유럽의약품청(EMA) 산하 인체용 의약품 위원회(CHMP)가 PRX-102에 대한 시판 허가를 권고하는 긍정적인 의견을 채택했다고 발표했습니다. 페구니갈시다제 알파(pegunigalsidase alfa)라고도 알려진 이 치료법은 파브리병 성인 환자 치료에 사용되는 최초이자 유일한 페길화 효소 치료제입니다.
시장 동향
신규 치료법에 대한 수요 증가
신규 치료법에 대한 수요 증가는 파브리병 치료 시장 점유율을 견인하는 주요 요인입니다. 파브리병 환자에게 더 나은 치료 결과를 제공할 수 있는 효과적이고 혁신적인 치료법에 대한 필요성이 점점 커지고 있습니다. 효소 대체 요법(ERT)과 같은 기존 치료법의 한계와 문제점으로 인해 대안적인 접근법에 대한 수요가 증가하고 있습니다.
샤페론 치료법 및 기질 감소 치료법과 같은 신규 치료법의 개발은 이 분야에서 상당한 관심과 기대를 불러일으켰습니다. 이러한 치료법은 기존 ERT에 비해 효능 향상, 편의성 증대, 치료 부담 감소와 같은 잠재적 이점을 제공합니다. 또한 ERT에 최적의 반응을 보이지 않거나 ERT 접근 또는 투여에 제약이 있는 환자에게 추가적인 치료 옵션을 제공합니다.

높은 치료 비용과 제한적인 치료 선택지
높은 치료 비용과 제한적인 치료 선택지는 파브리병 치료 시장의 성장을 저해하는 요인이 될 수 있습니다. 이러한 요인들은 환자와 의료 시스템 모두에 영향을 미칠 수 있습니다.
효소 대체 요법(ERT) 및 기타 신흥 치료법과 같은 파브리병 치료는 비용이 많이 들 수 있습니다. 이러한 치료의 높은 비용은 특히 의료 보장 범위가 제한적이거나 상환 정책이 불충분한 지역의 환자들에게 재정적 장벽을 만들 수 있습니다. 치료 비용 부담 능력은 치료 접근성과 시장 침투율에 상당한 영향을 미칠 수 있습니다.
파브리병 치료법은 발전해 왔지만, 다른 흔한 질환에 비해 치료 선택지는 여전히 제한적입니다. 이러한 제한된 선택은 환자가 자신의 질병 특성이나 치료 선호도에 가장 적합한 치료법을 받는 것을 제한할 수 있습니다. 또한 시장 경쟁을 저해하여 치료 비용 부담 능력과 혁신에 부정적인 영향을 미칠 수 있습니다.
코로나19 영향 분석
코로나19 팬데믹은 파브리병 치료 시장을 포함한 의료 산업에 심각한 영향을 미쳤습니다. 팬데믹으로 인한 경제적 여파는 의료 시스템, 의료비 지불자, 그리고 환자에게 영향을 미쳤습니다. 의료 예산이 빠듯해져 효소대체요법(ERT)과 같은 고가의 치료에 필요한 자금을 확보하는 데 어려움이 발생했을 수 있습니다.
환자들은 실직, 소득 감소, 보험 적용 범위 변경 등으로 재정적 어려움을 겪어 파브리병 치료 비용을 감당하거나 필요한 의료 서비스를 이용하기 어려웠을 수 있습니다.
팬데믹은 진행 중인 연구 활동과 임상 시험에 영향을 미쳤습니다. 환자 모집 제한, 연구 기관 폐쇄, 코로나19 연구 우선순위 지정 등으로 인해 많은 임상 시험이 일시적으로 중단되거나 지연되었습니다. 이로 인해 새로운 치료법 개발 및 평가가 지연되거나 파브리병 환자의 임상 시험 단계 치료법 접근이 제한되었을 수 있습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁은 파브리병 치료 시장에 상당한 영향을 미쳤습니다. 분쟁으로 인한 차질은 효소대체요법(ERT)을 포함한 의약품의 생산, 유통 및 공급에 영향을 미칠 수 있습니다. 또한 전문 클리닉, 진단 시설, 의료 전문가 접근과 같은 의료 서비스 제공에도 차질이 생길 수 있습니다.
분쟁은 파브리병 치료와 관련된 연구 개발 활동을 방해할 수 있습니다. 해당 지역의 기관이나 기업이 참여하는 임상 시험, 협력 및 연구 프로젝트는 지연되거나 중단될 수 있습니다. 이는 새로운 치료법 개발이나 기존 치료법 평가를 늦추어 파브리병 치료 시장 전반의 발전에 영향을 미칠 수 있습니다.
세분화 분석
전 세계 파브리병 치료 시장은 약물, 치료법, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
치료법별로는 효소 대체 요법(ERT) 부문이 시장 점유율을 주도할 것으로 예상됩니다.
효소 대체 요법(ERT) 시장은 2022년 전 세계 파브리병 치료 시장의 65.2%를 차지했습니다. 현재 파브리병에 대해 승인된 ERT 제품은 아갈시다제 알파(Replagal)와 아갈시다제 베타(Fabrazyme) 두 가지입니다. 이 제품들은 수년간 시장에 출시되어 상당한 시장 점유율을 확보했습니다. 승인된 ERT 옵션의 제공은 의료 전문가와 환자에게 신뢰할 수 있고 인정받은 치료법을 제공합니다.

2023년 5월, 바이오제약 회사인 프로탈릭스 바이오테라퓨틱스와 특수 의약품 회사인 키에시 그룹은 희귀 유전성 대사 질환인 파브리병 치료제 엘파브리오(Elfabrio)를 개발하여 FDA 승인을 받았습니다. 엘파브리오는 효소 대체 요법제입니다.
지역 분석
북미, 신규 치료법 도입 증가 및 탄탄한 의료 인프라로 최대 시장 점유율 차지
북미는 신규 치료법 도입 증가와 탄탄한 의료 인프라를 바탕으로 2022년 파브리병 치료 시장에서 43.2%의 시장 점유율을 차지했습니다.
북미는 파브리병 치료를 위한 신규 치료법 도입 및 활용에 앞장서 왔습니다. 이 지역은 혁신적인 치료법의 발견과 개발을 촉진하는 강력한 연구 개발 생태계를 보유하고 있습니다. 샤페론 요법 및 기질 감소 요법과 같은 대체 요법의 도입이 북미 지역에서 주목받으면서 환자들에게 추가적인 치료 선택권을 제공하고 있습니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Sanofi S.A, Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd., Amicus Therapeutics Inc., Amgen Inc., Bristol-Myers Squibb Company, Neuraltus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Idorsia Pharmaceuticals Ltd. 등이 있습니다.
보고서 구매 이유

• 약물, 치료법, 투여 경로, 유통 채널 및 지역별 글로벌 파브리병 치료 시장 세분화를 시각화하고 주요 상업적 자산과 업체를 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위해

• 모든 세그먼트를 포함한 파브리병 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 파브리병 치료 시장 보고서는 약 54개의 표, 46개의 그림, 그리고 195페이지 분량으로 구성됩니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Fabry Disease Treatment Market size reached US$ 1,876.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 3,287.2 million by 2030. The global Fabry disease treatment market is expected to exhibit a CAGR of 7.4% during the forecast period (2023-2030). The key market trend is the increasing focus on precision medicine and personalized therapies.
For instance, Personalized medicine, therapies tailored to patients' genetic and molecular makeup, is expected to improve outcomes and help direct patients away from therapies that don't work for them. It is aligned with the Triple Aim of improving patient experience, population health, and cost reduction.
Fabry disease is a rare genetic disorder characterized by the deficiency or malfunction of an enzyme called alpha-galactosidase A (AGA). This enzyme is responsible for breaking down a fatty substance called globotriaosylceramide (GL-3) or globotriaosylsphingosine (Lyso-GL-3). The accumulation of GL-3 or Lyso-GL-3 in various tissues and organs can lead to severe symptoms and complications.
The Fabry disease treatment market is driven by factors such as increasing awareness and diagnosis, increasing demand for novel therapies such as chaperone therapies and enzyme replacement therapies, advancements in treatment options, increasing R&D activities, and technological advancements.
For instance, in March 2023, Chiesi Global Rare Diseases, a part of the Chiesi Group and Protalix BioTherapeutics, a biopharmaceutical company announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for PRX-102. The therapy also known as pegunigalsidase alfa, is the first and only pegylated enzyme for the treatment of adult patients with Fabry disease
Market Dynamics
Increasing Demand For Novel Therapies
The increasing demand for novel therapies is indeed a major factor driving the market share in the Fabry disease treatment market. There is a growing need for more effective and innovative treatment options that can provide better outcomes for patients with Fabry disease. The limitations and challenges associated with current therapies, such as enzyme replacement therapy (ERT), have created a demand for alternative approaches.
The development of novel therapies, such as chaperone therapies and substrate reduction therapies, has generated significant interest and excitement in the field. These therapies offer potential advantages such as improved efficacy, convenience, and reduced treatment burden compared to traditional ERT. They provide additional treatment options for patients who may not respond optimally to ERT or have limitations in accessing or receiving ERT.
High Cost of the Treatment and Limited Treatment Options
The high cost of treatment and limited treatment options can present challenges and potentially hamper the growth of the Fabry disease treatment market. These factors can impact both patients and healthcare systems.
Fabry disease treatments, such as enzyme replacement therapy (ERT) and other emerging therapies, can be costly. The high cost of these treatments can create financial barriers for patients, particularly in regions with limited healthcare coverage or inadequate reimbursement policies. The affordability of therapies can significantly influence access to treatment and market penetration.
While there have been advancements in Fabry disease treatment, the availability of treatment options remains limited compared to more prevalent conditions. This limited choice can restrict patient access to therapies that are most suitable for their specific disease profile or treatment preferences. It can also limit competition in the market, potentially affecting affordability and innovation.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a profound impact on the healthcare industry, including the Fabry disease treatment market. The economic consequences of the pandemic have affected healthcare systems, payers, and patients. Healthcare budgets may have been strained, leading to potential challenges in funding expensive treatments like ERT.
Patients may have faced financial hardships due to job loss, reduced incomes, or changes in insurance coverage, making it difficult to afford Fabry disease treatments or access necessary healthcare services.
The pandemic had an impact on ongoing research activities and clinical trials. Many trials were temporarily halted or experienced delays due to restrictions on patient recruitment, site closures, and prioritization of COVID-19 research. This may have slowed down the development and evaluation of new treatments or limited access to investigational therapies for Fabry disease patients.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict has had a significant impact on the Fabry disease treatment market. The disruptions caused by a conflict could affect the production, distribution, and availability of medications, including enzyme replacement therapy (ERT). It may also disrupt the delivery of healthcare services, such as access to specialized clinics, diagnostic facilities, or healthcare professionals.
The conflict may disrupt research and development activities related to Fabry disease treatments. Clinical trials, collaborations, and research projects involving institutions or companies in the affected regions may face delays or interruptions. This can slow down the development of new therapies or the evaluation of existing treatments, affecting the overall advancement of the Fabry disease treatment market.
Segment Analysis
The global Fabry disease treatment market is segmented based on drugs, treatment, route of administration, distribution channel, and region.
Based on Treatment, the Enzyme Replacement Therapy (ERT) Segment is Expected to Dominate the Market Share
The market for enzyme replacement therapy (ERT) holds the 65.2% of the global Fabry disease treatment market share in 2022. Currently, there are two approved ERT products for Fabry disease: agalsidase alfa (Replagal) and agalsidase beta (Fabrazyme). These products have been in the market for several years and have established a significant market presence. The availability of approved ERT options provides healthcare professionals and patients with a reliable and recognized treatment approach.
In May 2023, Protalix BioTherapeutics, a biopharmaceutical company, and Chiesi Group, a specialty pharmaceutical company developed a drug called Elfabrio is approved by FDA for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.
Geographical Analysis
North America Holds the Largest Market Share Due to the Increasing Adoption of Novel Therapies and the Presence of a Strong Healthcare Infrastructure
North America holds the 43.2% market share for the Fabry disease treatment market in 2022 due to the increasing adoption of novel therapies and the presence of strong healthcare infrastructure in the region.
North America has been at the forefront of adopting and integrating novel therapies for Fabry disease treatment. The region has a robust research and development ecosystem, which facilitates the discovery and development of innovative treatment options. The introduction of alternative therapies, such as chaperone therapies and substrate reduction therapies, has gained traction in North America, providing additional treatment choices for patients.
Competitive Landscape
The major global players in the market include Sanofi S.A, Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd., Amicus Therapeutics Inc., Amgen Inc., Bristol-Myers Squibb Company, Neuraltus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., and Idorsia Pharmaceuticals Ltd.
Why Purchase the Report?
• To visualize the global Fabry disease treatment market segmentation based on drugs, treatment, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Fabry disease treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global Fabry disease treatment market report would provide approximately 54 tables, 46 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drugs
3.2. Snippet by Treatment
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Novel Therapies
4.1.1.2. Increasing R&D Activities
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.2.2. Limited treatment options
4.1.3. Opportunity
4.1.3.1. Advancements in Treatment Options
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Drugs
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
7.1.2. Market Attractiveness Index, By Drugs
7.2. Agalsidase Beta (Fabrazyme/Replagal)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Migalastat (Galafold)
7.4. Others
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Enzyme Replacement Therapy (ERT)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chaperone Treatment
8.4. Substrate Reduction Therapy (SRT)
8.5. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Sanofi S.A.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Takeda Pharmaceutical Company Ltd
13.3. Teva Pharmaceutical Industries Ltd.
13.4. Amicus Therapeutics Inc.
13.5. Amgen Inc.
13.6. Bristol-Myers Squibb Company
13.7. Neuraltus Pharmaceuticals Inc.
13.8. Novartis AG
13.9. Pfizer Inc.
13.10. Idorsia Pharmaceuticals Ltd.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Sanofi S.A., 4.	Key Developments, Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd., Amicus Therapeutics Inc., Amgen Inc., Bristol-Myers Squibb Company, Neuraltus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Idorsia Pharmaceuticals Ltd.

표 목록 (Tables)

List of Tables

Table 1 Global Fabry Disease Treatment Market Value, By Drugs, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Fabry Disease Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Fabry Disease Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Fabry Disease Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Fabry Disease Treatment Market Value, By Drugs, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)

Table 8 Global Fabry Disease Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 10 Global Fabry Disease Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 12 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 14 Global Fabry Disease Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Fabry Disease Treatment Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)

Table 17 North America Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 18 North America Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 North America Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 North America Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)

Table 22 South America Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 South America Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 24 South America Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 25 South America Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)

Table 27 Europe Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 28 Europe Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 29 Europe Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 30 Europe Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East & Africa Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)

Table 37 Middle East & Africa Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 38 Middle East & Africa Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 39 Middle East & Africa Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 40 Sanofi S.A.: Overview

Table 41 Sanofi S.A.: Product Portfolio

Table 42 Sanofi S.A.: Key Developments

Table 43 Takeda Pharmaceutical Company Ltd: Overview

Table 44 Takeda Pharmaceutical Company Ltd: Product Portfolio

Table 45 Takeda Pharmaceutical Company Ltd: Key Developments

Table 46 Teva Pharmaceutical Industries Ltd.: Overview

Table 47 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 48 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 49 Amicus Therapeutics Inc.: Overview

Table 50 Amicus Therapeutics Inc.: Product Portfolio

Table 51 Amicus Therapeutics Inc.: Key Developments

Table 52 Amgen Inc.: Overview

Table 53 Amgen Inc.: Product Portfolio

Table 54 Amgen Inc.: Key Developments

Table 55 Bristol-Myers Squibb Company: Overview

Table 56 Bristol-Myers Squibb Company: Product Portfolio

Table 57 Bristol-Myers Squibb Company: Key Developments

Table 58 Neuraltus Pharmaceuticals Inc.: Overview

Table 59 Neuraltus Pharmaceuticals Inc.: Product Portfolio

Table 60 Neuraltus Pharmaceuticals Inc.: Key Developments

Table 61 Novartis AG: Overview

Table 62 Novartis AG: Product Portfolio

Table 63 Novartis AG: Key Developments

Table 64 Pfizer Inc.: Overview

Table 65 Pfizer Inc.: Product Portfolio

Table 66 Pfizer Inc.: Key Developments

Table 67 Idorsia Pharmaceuticals Ltd.: Overview

Table 68 Idorsia Pharmaceuticals Ltd.: Product Portfolio

Table 69 Idorsia Pharmaceuticals Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 2 Global Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 3 Global Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 4 Global Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 5 Global Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 6 Global Fabry Disease Treatment Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Fabry Disease Treatment Market Y-o-Y Growth, By Drugs, 2022-2030 (%)

Figure 7 Agalsidase Beta (Fabrazyme/Replagal) Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 8 Migalastat (Galafold) Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 9 Global Fabry Disease Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 10 Enzyme Replacement Therapy (ERT) Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 11 Chaperone Treatment Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 12 Substrate Reduction Therapy (SRT) Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 13 Others Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 14 Global Fabry Disease Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 15 Oral Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 16 Parenteral Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 17 Others Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 18 Global Fabry Disease Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 Hospitals Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 20 Retail Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 21 Online Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 22 Others Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 23 Global Fabry Disease Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 25 Asia-Pacific Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 26 Europe Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 27 South America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 28 Middle East and Africa Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 29 North America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 30 North America Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 31 North America Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 32 North America Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 33 North America Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 34 North America Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 35 South America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 36 South America Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 37 South America Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 38 South America Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 39 South America Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 40 South America Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 41 Europe Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 42 Europe Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 43 Europe Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 44 Europe Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 45 Europe Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 46 Europe Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 47 Asia-Pacific Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 48 Asia-Pacific Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 49 Asia-Pacific Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 50 Asia-Pacific Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 51 Asia-Pacific Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 52 Asia-Pacific Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)

Figure 53 Middle East & Africa Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)

Figure 54 Middle East & Africa Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)

Figure 55 Middle East & Africa Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)

Figure 56 Middle East & Africa Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 57 Middle East & Africa Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 58 Sanofi S.A.: Financials

Figure 59 Takeda Pharmaceutical Company Ltd: Financials

Figure 60 Teva Pharmaceutical Industries Ltd.: Financials

Figure 61 Amicus Therapeutics Inc.: Financials

Figure 62 Amgen Inc.: Financials

Figure 63 Bristol-Myers Squibb Company: Financials

Figure 64 Neuraltus Pharmaceuticals Inc.: Financials

Figure 65 Novartis AG: Financials

Figure 66 Pfizer Inc.: Financials

Figure 67 Idorsia Pharmaceuticals Ltd.: Financials

세계 파브리병 치료 시장 – 2023-2030

Global Fabry Disease Treatment Market - 2023-2030